AstraZeneca's key immunotherapy drug durvalumab was shown to reduce the risk of stage III lung cancer worsening or causing death in a trial, the pharmaceutical company said on Friday.
The trial results are a boost for a product the company hopes will become a blockbuster drug with sales in the billions of dollars. Astra said it was in active discussion with the authorities over its plans for regulatory submission.
The drug, which will have the brand name Imfinzi, works by helping the body's immune cells kill cancer, offering an alternative to chemotherapy.
The trial found that Imfinzi "significantly reduces risk of disease worsening or death in phase III pacific trial for stage III unresectable lung cancer", meaning inoperable lung cancer.